Valitor

Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC

Retrieved on: 
Wednesday, July 19, 2023

BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi, Ph.D., as vice president of CMC (Chemistry, Manufacturing and Controls).

Key Points: 
  • BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi, Ph.D., as vice president of CMC (Chemistry, Manufacturing and Controls).
  • “We are delighted to welcome Omkar to Valitor as he brings deep knowledge and a wealth of experience that will be instrumental in the next phase of our growth,” said Steven Lo, chief executive officer of Valitor.
  • “Beyond his proven technical capabilities, impressive tenure as an experienced technical operations leader and successful CMC track record, Omkar has also proven his adeptness at building and leading high-performing teams in both small startup companies and big pharma.
  • Dr. Joshi has extensive experience working across various modalities including recombinant proteins, monoclonal antibodies, ADCs, cell therapies and gene therapies.

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Monday, April 24, 2023

These data are being presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.

Key Points: 
  • These data are being presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.
  • The preclinical results demonstrated highly-localized and sustained drug exposure to ocular tissues and also confirmed the anti-VEGF bioactivity of VLTR-557.
  • In addition, VLTR-557 exhibited high binding affinity to VEGF-A and remained stable under physiologic conditions for six months.
  • These data suggest that a single intravitreal (ITV) injection of VLTR-557 has potential to maintain clinical efficacy for more than six months.

Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 10, 2023

BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that data reviewing the therapeutic potential of its Multivalent Polymer (MVP) technology in oncology has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Key Points: 
  • BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that data reviewing the therapeutic potential of its Multivalent Polymer (MVP) technology in oncology has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
Thursday, March 23, 2023

BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that two abstracts have been accepted for poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.

Key Points: 
  • BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that two abstracts have been accepted for poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.
  • Preclinical data on VLTR-557, a long-acting anti-VEGF biologic being developed for wet age-related macular degeneration, and preclinical data on a single-domain anti-TNFα antibody for non-infectious uveitis, will be presented at the congress.

Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit

Retrieved on: 
Thursday, December 1, 2022

The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.

Key Points: 
  • The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.
  • Preclinical studies have demonstrated that VLTR-557 has an exceptional overall safety profile and does not leave residual depot materials within the eye.
  • VLTR-557 was created using the companys Multivalent Polymer (MVP) technology platform, which enables the development of novel macromolecular compounds through the use of biopolymers that can be engineered with multiple copies of bioactive molecules.
  • We are addressing this challenge with the development of our next generation anti-VEGF therapy, VLTR-557, and we look forward to keeping the community apprised of our progress as we begin IND-enabling studies.

Global Contactless Payment Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts

Retrieved on: 
Tuesday, December 7, 2021

DUBLIN, Dec. 7, 2021 /PRNewswire/ -- The "Contactless Payment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 7, 2021 /PRNewswire/ -- The "Contactless Payment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global contactless payment market reached a value of US$ 10.50 Billion in 2020 and is expected to reach US$ 20.7 Billion by 2026.
  • Looking forward, the publisher expects the global contactless payment market to grow at a CAGR of around 18% during 2021-2026.
  • What is the structure of the global contactless payment market and who are the key players?

Leadgence, a fast-growing platform for dynamic SMB data and analytics for marketing, sales and growth teams, announcing new advisory Board member, Mr. Roger Alexander.

Retrieved on: 
Wednesday, August 25, 2021

Roger Alexander has spent over 33 years as a leader in the merchant sector of the financial services industry, focusing on payment solutions.

Key Points: 
  • Roger Alexander has spent over 33 years as a leader in the merchant sector of the financial services industry, focusing on payment solutions.
  • "The continuous struggle to decrease customer churn for banks is a good example for how Leadgence smart data can make a real difference.''
  • "We are excited to formally welcome Roger to our advisory board," said Leadgence Co-Founder and CEO Leetal Gruper.
  • Leadgence's targeted and dynamic data is used by marketing, sales and growth teams of leading financial services companies to drive sales to SMBs in the US, UK, Canada and Ireland.